A billionaire-backed biotech startup, R3 Bio, is developing genetically engineered 'organ sacks'—whole organ systems without a brain—as an alternative to animal testing. This idea comes as the Trump administration phases out animal experimentation across the federal government. A cofounder states the long-term goal is to create human versions.
R3 Bio, a startup supported by a billionaire, has introduced a novel approach to address the decline in animal testing. The company aims to grow nonsentient 'organ sacks,' which are genetically engineered whole organ systems lacking a brain. This technology is positioned as a replacement for lab animals in research and testing scenarios. The initiative aligns with recent policy changes under the Trump administration, which is phasing out the use of animal experimentation across the federal government. According to a cofounder quoted in a WIRED article published on March 23, 2026, the long-term objective is to develop human versions of these organ systems. The proposal raises discussions in biotech and ethics circles, with keywords associated including biotech, ethics, biology, animals, and organ transplants. No further details on funding, timelines, or specific billionaire backers were provided in the available sources.
